Clinical Trial Update: Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anlotinib plus sintilimab for non-small cell lung cancer in patients with resistance to first-generation EGFR-TKIs and T790M n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: First Hospital of Shijiazhuang City | Conditions: Carcinoma, Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN